Related Experiment Video
Updated: Jul 14, 2026
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
[Visual course for proliferative diabetic retinopathy after pars plana vitrectomy]
1Department of Ophthalmology, Saiseikai Niigata Daini Hospital, 280-7 Terachi, Niigata-shi 950-1104, Japan.
Nippon Ganka Gakkai Zasshi
|June 1, 2007
Summary
Visual acuity in proliferative diabetic retinopathy improves after vitrectomy, with earlier gains observed when triamcinolone acetonide (TA) is used. Recovery times varied by maculopathy type, averaging 9-19 months.
Area of Science:
- Ophthalmology
- Retinal Surgery
Context:
- Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss.
- Pars plana vitrectomy is a surgical intervention for PDR complications.
Purpose:
- To retrospectively analyze the visual recovery timeline following pars plana vitrectomy in eyes with PDR.
- To compare visual outcomes based on the type of diabetic maculopathy and the use of triamcinolone acetonide (TA).
Summary:
- This study reviewed 28 eyes with PDR undergoing vitrectomy, with visual acuity tracked for at least 6 months.
- The mean time to achieve best visual acuity was 14.7 months, with variations based on maculopathy type (9-19 months).
- Vitrectomy combined with TA demonstrated significantly earlier visual improvement compared to vitrectomy alone (p=0.03).
Impact:
- Provides insights into the expected visual recovery trajectory after PDR surgery.
- Highlights the potential benefit of adjunctive TA in accelerating visual rehabilitation.
- Informs clinical management and patient expectations for visual outcomes in PDR.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...